Revenue
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sunshine Biopharma Inc. (SBFM)
Price$1.14Cached quote
Net income
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $36.3M | $34.9M | $24.1M | $4.3M | $228,426 | $71,410 | $21,121 | $0 | $0 | $0 | $1,708 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $12.3M | $10.7M | $8.3M | $1.7M | $110,596 | $45,563 | $10,071 | $0 | $0 | — | — | — | — | — | — | — |
| Gross margin | 33.76% | 30.60% | 34.61% | 39.04% | 48.42% | 63.80% | 47.68% | — | — | — | — | — | — | — | — | — |
| Research & development | $604,308 | $933,902 | $1.9M | $811,858 | $672,209 | $1,728 | $15,204 | $12,800 | $0 | $32,793 | $8,657 | $327,000 | $137,400 | $1,829 | $142,650 | $0 |
| Operating expenses | $18.5M | $16.5M | $13.1M | $28.7M | $2.6M | $622,437 | $651,707 | $1.2M | $857,190 | — | — | — | — | — | — | — |
| Operating income | −$6.2M | −$5.8M | −$4.8M | −$27.0M | −$2.4M | −$576,874 | −$641,636 | −$1.2M | −$857,190 | −$993,108 | −$780,277 | −$1.8M | −$1.9M | −$706,680 | −$556,202 | — |
| Operating margin | −17.15% | −16.67% | −19.86% | −621.33% | −1,068.24% | −807.83% | −3,037.91% | — | — | — | −45,683.67% | — | — | — | — | — |
| EBITDA | −$5.9M | −$5.6M | −$4.6M | −$27.0M | −$2.4M | −$562,808 | −$627,862 | −$1.1M | −$850,561 | −$932,377 | −$776,026 | −$1.8M | — | — | — | — |
| EBITDA margin | −16.24% | −16.02% | −19.24% | −620.76% | −1,062.66% | −788.14% | −2,972.69% | — | — | — | −45,434.78% | — | — | — | — | — |
| Net income | −$6.0M | −$5.1M | −$4.5M | −$26.7M | −$12.4M | −$2.8M | −$1.7M | −$2.2M | −$1.0M | −$3.5M | −$1.7M | −$1.9M | −$2.5M | −$707,952 | −$556,202 | −$537,382 |
| Net profit margin | −16.46% | −14.72% | −18.70% | −615.44% | −5,444.41% | −3,898.74% | −7,860.85% | — | — | — | −96,774.47% | — | — | — | — | — |
| Basic EPSper basic share | -$14.40 | -$73,200.00 | -$3,513.60 | -$35,200.00 | -$95,200.00 | -$54,600.00 | -$3,000.00 | -$14,200.00 | -$8,000.00 | -$80,000.00 | -$80,000.00 | -$240,000.00 | -$320,000.00 | -$80,000.00 | -$160,000.00 | -$160,000.00 |
| Diluted EPSper diluted share | -$14.40 | -$73,200.00 | -$3,513.60 | -$35,200.00 | -$95,200.00 | — | — | — | — | — | — | — | — | — | — | — |
Owners
Reported shareholders
≈4.19%of listed shares
NATAN DAVID100K shares · Apr 14, 2026
View holders
| Holder | % owned |
|---|---|
NATAN DAVID | ≈4.19%100K shares |
JANE STREET GROUP, LLC | 0.63%14.97K shares |
MORGAN STANLEY | 0.02%385 shares |
SBI Securities Co., Ltd. | <0.01%162 shares |
NATIONAL BANK OF CANADA /FI/ | <0.01%5 shares |
OSAIC HOLDINGS, INC. | <0.01%2 shares |
Caitong International Asset Management Co., Ltd | <0.01%1 shares |
Farther Finance Advisors, LLC | <0.01%1 shares |
TD Waterhouse Canada Inc. | <0.01%1 shares |
Roy Michel | ≈<0.01%1 shares |
Strive Financial Group ,LLC | <0.01%1 shares |
Percentages use 2.39M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data